Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Services » Servicestothe Health Industry
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| LH | Laboratory Corp. of America Holdings | 0.38% | 195.46 | 2.4% | $132.28m | |
| DGX | Quest Diagnostics, Inc. | 0.62% | 112.86 | 4.2% | $106.23m | |
| SYNH | Syneos Health, Inc. | -0.41% | 65.62 | 0.0% | $21.52m | |
| NRC | National Research Corp. | -0.62% | 68.92 | 0.0% | $1.84m | |
| AMEH | Apollo Medical Holdings, Inc. | -1.89% | 17.15 | 0.0% | $0.96m | |
| IDXG | Interpace Biosciences, Inc. | 5.26% | 8.80 | 24.1% | $0.72m | |
| PLX | Protalix Biotherapeutics, Inc. | -5.49% | 3.27 | 56.8% | $0.30m | |
| BASI | Bioanalytical Systems, Inc. | -7.06% | 4.61 | 0.2% | $0.26m | |
| PMD | Psychemedics Corp. | 0.54% | 9.25 | 0.7% | $0.20m |
Company Profile
Interpace Biosciences, Inc. operates as an bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX and PathFinderTG which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.